An underground market for unlicensed weight-loss medications is propelled by social media fitness personalities and vendors on messaging platforms, according to recent findings.
Experimental Treatment Acquiring Traction Via Social Media
Retatrutide, which is still in clinical trials, is being advertised by online personalities for its supposed weight-reducing properties. Followers are urged to message these profiles directly for source information, while also receiving promotional offers.
Active Trade on Social Networks
Separately, a flourishing market exists on messaging services, where groups with thousands of members share “before and after” images, injection guides and assertions of next-day British shipping. Sellers promote the drug there before redirecting buyers to WhatsApp for purchases.
Learning About The Experimental Drug
Retatrutide is an investigational injection created by US drugmaker Eli Lilly. The drug affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials indicate it could help patients lose up to 25% of their body weight. Nicknamed the “triple G”, the substance is being promoted online as the next Ozempic.
Medical Experts Voice Concerns
However, doctors and pharmacists have cautions that the sale of what remains an unlicensed drug in the United Kingdom is a cause for concern and could lead to individuals administering substances of unknown origin.
Several professionals stated the popularity for the experimental drug could be connected to the increasing cost of licensed slimming treatments such as Mounjaro.
Regulatory Position and Implementation
Marketing the unapproved drug on social media or Telegram is prohibited in the United Kingdom, as it is an unapproved medication that cannot be promoted or distributed for personal consumption under the Human Medicines Regulations 2012.
Some content creators try to circumvent the rules by calling to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but advertising and distribution can still violate medicines, marketing, and consumer regulations, potentially leading to fines, legal action or prison.
Platform Reaction and Material Removal
According to TikTok, the service has taken down problematic material and prohibited associated hashtags and search suggestions. The organization stated it was dedicated to maintaining the service safe and investing in strengthening enforcement strategies.
Digital Trading Activities
Research also found groups with up to nine thousand participants selling the experimental drug using the platform's built-in discovery tool, which operates like a online catalog. Entering “retatrutide” immediately brings up channels with numerous of members, filled with photos of slimming results, glowing reviews and step-by-step guides for preparing or injecting at residence.
After minutes of joining one community, a vendor shared contact information, where the majority of transactions occur. The seller provided an instruction manual and promised delivery within 48 hours. When asked whether the substance was genuine, one seller responded: “You can’t be sure.” Another provided a photo of a supposed testing documentation. Not one inquired about body mass, medical conditions or past usage.
Item Details and Costs
Inside these groups, messages show black plastic packages with postal service stickers, stating to contain fresh supplies. One message read: “It took eight of us to load them this morning.”
Buyers can choose between powder vials, mixed at home with sterile water, or ready-to-use pens usually priced at 160 pounds for 20 milligrams. When asked how long a pen should be used, vendors give contradictory answers ranging from a several days to “depends on your body”.
Platform Moderation and Security Measures
A spokesperson for Telegram stated it regularly monitored harmful material on its service including material that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.
Medical Expert Warnings
“People are administering materials they cannot confirm. Even if the research behind retatrutide is sound, these digital versions may not include what they advertise,” said Jason Murphy, the head of pharmacy at Chemist4U.
Dr Crystal Wyllie of Asda Online Doctor connected the increase in interest to recent cost increases for approved slimming drugs such as Mounjaro. “With prices increasing, patients are turning to online platforms. But fake injections are highly risky. You cannot know what’s inside or whether the conditions they were made in was clean,” she explained.
Her team has already seen patients harmed by self-injection from unverified sources. “We recognize the disappointment, but buying from messaging apps or communication platforms is gambling with your health,” said the doctor. “These materials could be contaminated or improperly measured.”
Producer Position
A spokesperson from the pharmaceutical company said the substance was in third stage clinical trials and had not been evaluated or authorized by any regulatory agency anywhere in the world. “Consequently at this point no one can market [it] for personal consumption,” they explained, noting that any item “misleadingly claiming itself as a company investigational substance not yet authorized … may expose patients to possibly serious health risks”.
